There is some good news from the world of drug development today. Dynavax Technologies has revealed positive Phase II results comparing two different vaccination schedules for its hepatitis B vaccine HEPLISAV. The primary endpoint was comparative seroprotection after the second dose, and the trial showed that complete seroprotection is achieved whether the second dose is administered one or two months after the first. Dynavax will be launching a Phase III trial of the vaccine before the end of 2006.
- here's the company press release